These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15304607)

  • 1. Subthalamic deep brain stimulation masking possible malignant syndrome in Parkinson disease.
    Linazasoro G; Van Blercom N; Castro A; Dapena MD
    Neurology; 2004 Aug; 63(3):589-90. PubMed ID: 15304607
    [No Abstract]   [Full Text] [Related]  

  • 2. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

  • 3. Selegiline and excess mortality.
    Oakes D
    Clin Neuropharmacol; 1997 Dec; 20(6):542. PubMed ID: 9403228
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
    Olanow CW; Godbold JH; Koller W
    BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
    [No Abstract]   [Full Text] [Related]  

  • 5. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
    Breteler MM
    BMJ; 1998 Apr; 316(7139):1182-3. PubMed ID: 9552992
    [No Abstract]   [Full Text] [Related]  

  • 6. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Heinonen E; Myllylä V
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280-2. PubMed ID: 9703195
    [No Abstract]   [Full Text] [Related]  

  • 7. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Coyle J; Hobson P; Meara J
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280; author reply 281-2. PubMed ID: 9703194
    [No Abstract]   [Full Text] [Related]  

  • 8. Pallidotomy in Parkinson's disease.
    Temlett JA
    S Afr Med J; 1996 Oct; 86(10):1248-9. PubMed ID: 8955725
    [No Abstract]   [Full Text] [Related]  

  • 9. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 10. A 77-year-old man with Parkinson's disease and hyperthermia.
    Madigan EJ
    J Emerg Nurs; 2008 Jun; 34(3):229-30. PubMed ID: 18558256
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of malignant syndrome associated with a parkinsonism patient.
    Sanga M; Nomura S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2003 Apr; 23(2):91-5. PubMed ID: 12762221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of Parkinson's disease.
    Eadie MJ
    Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
    Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
    Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease.
    Kedia S; Moro E; Tagliati M; Lang AE; Kumar R
    Neurology; 2004 Dec; 63(12):2410-2. PubMed ID: 15623715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.